Advertisement
Retraction
Open Access | 10.1172/JCI194718
Find articles by Feng, H. in: PubMed | Google Scholar
Find articles by Lopez, G. in: PubMed | Google Scholar
Find articles by Kim, C. in: PubMed | Google Scholar
Find articles by Alvarez, A. in: PubMed | Google Scholar
Find articles by Duncan, C. in: PubMed | Google Scholar
Find articles by Nishikawa, R. in: PubMed | Google Scholar
Find articles by Nagane, M. in: PubMed | Google Scholar
Find articles by Su, A. in: PubMed | Google Scholar
Find articles by
Auron, P.
in:
PubMed
|
Google Scholar
|
Find articles by Hedberg, M. in: PubMed | Google Scholar
Find articles by Wang, L. in: PubMed | Google Scholar
Find articles by Raizer, J. in: PubMed | Google Scholar
Find articles by Kessler, J. in: PubMed | Google Scholar
Find articles by Parsa, A. in: PubMed | Google Scholar
Find articles by Gao, W. in: PubMed | Google Scholar
Find articles by Kim, S. in: PubMed | Google Scholar
Find articles by Minata, M. in: PubMed | Google Scholar
Find articles by Nakano, I. in: PubMed | Google Scholar
Find articles by Grandis, J. in: PubMed | Google Scholar
Find articles by McLendon, R. in: PubMed | Google Scholar
Find articles by Bigner, D. in: PubMed | Google Scholar
Find articles by Lin, H. in: PubMed | Google Scholar
Find articles by Furnari, F. in: PubMed | Google Scholar
Find articles by Cavenee, W. in: PubMed | Google Scholar
Find articles by Hu, B. in: PubMed | Google Scholar
Find articles by Yan, H. in: PubMed | Google Scholar
Find articles by Cheng, S. in: PubMed | Google Scholar
Published May 15, 2025 - More info
Aberrant activation of EGFR in human cancers promotes tumorigenesis through stimulation of AKT signaling. Here, we determined that the discoidina neuropilin-like membrane protein DCBLD2 is upregulated in clinical specimens of glioblastomas and head and neck cancers (HNCs) and is required for EGFR-stimulated tumorigenesis. In multiple cancer cell lines, EGFR activated phosphorylation of tyrosine 750 (Y750) of DCBLD2, which is located within a recently identified binding motif for TNF receptor-associated factor 6 (TRAF6). Consequently, phosphorylation of DCBLD2 Y750 recruited TRAF6, leading to increased TRAF6 E3 ubiquitin ligase activity and subsequent activation of AKT, thereby enhancing EGFR-driven tumorigenesis. Moreover, evaluation of patient samples of gliomas and HNCs revealed an association among EGFR activation, DCBLD2 phosphorylation, and poor prognoses. Together, our findings uncover a pathway in which DCBLD2 functions as a signal relay for oncogenic EGFR signaling to promote tumorigenesis and suggest DCBLD2 and TRAF6 as potential therapeutic targets for human cancers that are associated with EGFR activation.
Haizhong Feng, Giselle Y. Lopez, Chung Kwon Kim, Angel Alvarez, Christopher G. Duncan, Ryo Nishikawa, Motoo Nagane, An-Jey A. Su, Philip E. Auron, Matthew L. Hedberg, Lin Wang, Jeffery J. Raizer, John A. Kessler, Andrew T. Parsa, Wei-Qiang Gao, Sung-Hak Kim, Mutsuko Minata, Ichiro Nakano, Jennifer R. Grandis, Roger E. McLendon, Darell D. Bigner, Hui-Kuan Lin, Frank B. Furnari, Webster K. Cavenee, Bo Hu, Hai Yan, Shi-Yuan Cheng
Original citation: J Clin Invest. 2014;124(9):3741–3756. https://doi.org/10.1172/JCI73093
Citation for this retraction: J Clin Invest. 2025;135(10):e194718. https://doi.org/10.1172/JCI194718
Errors were recently identified in Figures 2E, 4A, 5B, and 5C, Supplemental Figure 4A, Supplemental Figure 14, Supplemental Figure 19, and the unedited blot images for Figure 5B. Although the authors have indicated that original source data support the findings in these figure panels, the corresponding authors are retracting the article due to the number of errors.
See the related article at EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.